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A number of neurodegenerative diseases principally affect
humans as they age and are characterized by the loss
of specific groups of neurons in different brain regions.
Although these disorders are generally sporadic, it is
now clear that many of them have a substantial genetic
component. As genes are the raw material with which
evolution works, we might benefit from understanding
these genes in an evolutionary framework. Here, I will
discuss how we can understand whether evolution has
shaped genes involved in neurodegeneration and the
implications for practical issues, such as our choice of
model systems for studying these diseases, and more
theoretical concerns, such as the level of selection against
these phenotypes.
Introduction
Evolutionary theory, modified to include our modern molec-
ular views on genetics, permeates all aspects of modern
biology. Understanding human biology therefore incorpo-
rates an acknowledgement that our genetic heritage is
shaped by the evolutionary forces that have led to humans
occupying our current niche. And it should not be surprising
that, as a major aspect of our biology, the near universal
experience of human disease can also be viewed through
the evolutionist’s prism.
Here, I will discuss the relationship of evolution to age-
related neurodegenerative disorders. This group of diseases
is characterized by a common property — the progressive
loss of relatively specific groups of neurons. The distinguish-
ing feature of each disease is that, during the aging process,
different groups of neurons are lost and these losses corre-
late with different clinical features. For example, neuronal
loss in the hippocampus and cerebral cortex underlies
many of the memory problems associated with Alzheimer’s
disease (AD), whereas loss of Purkinje cells in the cere-
bellum is characteristic of the spinocerebellar ataxias. These
symptoms are often profoundly disabling and sometimes
fatal; loss of the neurons that innervate the diaphragm in
amyotrophic lateral sclerosis (ALS) leads to an inability to
breathe.
Additionally, in many, but not all, neurodegenerative con-
ditions, there are other pathological events, including the
accumulation of specific proteins in those neurons that
survive. Often these are aggregated and insoluble and,
more importantly, often the genes that encode these patho-
logical proteins either cause inherited forms of disease and/
or act as genetic risk factors. Therefore, pathology, clinical
phenotype and causal variation in specific genes are linked.
Two questions are worth discussing here to allow us to
understand the evolutionary context of neurodegeneration-
associated genes and proteins. The first regards the ways
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that are related to mutations associated with neurodegener-
ative diseases. This has practical implications, for example,
in assigning pathogenicity to specific mutations in genes or
for understanding how far we can extrapolate from model
systems to human diseases. The second consideration is
whether evolutionary forces have shaped these degenera-
tive diseases. To provide a detailed example, I will first cover
Parkinson’s disease (PD), a disorder that illustrates many of
the key points under discussion here. (I admit this is biased
by my own research interests, so refer the interested reader
to other review articles about the genetics of neurodegener-
ative diseases more generally [1,2].)
Genes Associated with Parkinson’s Disease
PD conforms to the general description of neurodegenera-
tion as outlined above, i.e. involving the loss of neurons
with accumulation of pathological proteins, but there are
specific events that define this disease. First, there is the
loss of neurons that project from the substantia nigra pars
compacta to the striatum and produce the neurotransmitter
dopamine (Figure 1). Other brain areas are involved in PD but
it is the death of these dopamine-producing neurons that is
responsible for some of the prominent problems with move-
ment seen in people living with PD — tremor, slowness of
movement, and problems with posture. Loss of dopamine-
producing neurons is probably fairly well established by
the time clinical signs are noticed and replacement of dopa-
mine has dramatic effects on symptoms, at least early in the
disease course [3]. A second pathological characteristic of
PD and related disorders is the presence of Lewy bodies
and Lewy neurites [4]. These are accumulations of proteins
and lipids in many of the neurons that survive to the end of
the disease. Of the protein components, one of themost reli-
able markers is a-synuclein (Figure 2). Other reviews have
covered the genetics of PD [5,6], so here I will outline some
of the key discoveries that allow for discussion of the nature
of the disease in an evolutionary context.
a-Synuclein
Critically for understanding the pathophysiology of PD, a
series of point mutations in the gene that encodes a-synu-
clein, SNCA, are associated with dominantly inherited PD.
The first reported was Ala53Thr (A53 T) in a series of families
from Greek and Italian descent [7]. Additional amino acid
variants include A30P [8] and E46K [9].
Other PD-associated mutations involve a tandem triplica-
tion [10] or duplication [11] of the normal SNCA locus. These
genetic observations show that the normal protein has the
capacity to cause damage to the brain at higher than nor-
mal expression levels. Additionally, common variants at the
same locus are risk factors for PD [12]. These risk variants
are not strong enough to produce Mendelian inheritance,
but instead increase the chances of developing PD by about
20–40%over the lifetime of an individual. It is likely that these
common variants around the SNCA locus will also produce
higher expression of a-synuclein, but not to the levels seen
with triplication or duplication, although this is not yet proven
[13]. Therefore, studies of a-synuclein show that inherited
and sporadic forms of PDmight have some common etiopa-
thological mechanisms.
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Figure 1. The pathology of Parkinson’s disease.
The cartoon shows a simplified view of the main neuropathological events in PD at three levels from left to right. At the level of the brain, a major
pathway is degeneration of the dopaminergic projections from the substantia nigra (in black) to the striatum (in purple), both of which are in the
midbrain underneath the cerebral cortex. At the level of substantia nigra, the neurons that form the presynaptic portion of this pathway are nor-
mally melanized and are easily identified by this pigment in control brains (upper panel). In contrast, the loss of neurons in this region is so
substantial that the whole area becomes depigmented in PD cases (lower panel). Of the few remaining cells, many show pathological changes,
including the accumulation of proteins and lipids in Lewy bodies. A characteristic component of Lewy bodies is a-synuclein, encoded by the
SNCA gene, which is known to increase the risk of PD.
Current Biology Vol 22 No 17
R754How a-synuclein mutations lead to PD is not quite clear.
In vitro, a-synuclein is prone to protein aggregation and it
is the aggregated forms of synuclein that are found in Lewy
bodies [14]. Specifically, a-synuclein aggregates into large,
insoluble assemblies with a b-sheet-like structure, similar
to b-amyloid, another aggregating protein associated with
neurodegeneration. However, it is not known whether fully
aggregated fibrils of a-synuclein, as deposited in Lewy
bodies, cause neuronal death or whether some other bio-
physical species is more important. Attempts to answer
this question have generally found a correlation between
the amount of small oligomeric assemblies of a-synuclein
and toxic effects on neurons [15,16]. Even within the range
of oligomers, certain species may be especially toxic, as
has been shown recently using single-molecule techniques
to identify specific types of oligomers that can generate
high levels of oxidative stress when applied to primary
neurons [17].
A53T is more prone to form all types of aggregates (from
oligomers to fibrils) than normal human a-synuclein. This
enhanced aggregation capacity is also seen with several
alanine-to-threonine mutations in other amyloidogenic pro-
teins that cause human diseases [18]. A similar enhancement
in aggregation is seen with the E46K mutation, which occurs
at a more conserved residue [19,20]. The A30P mutation
readily makes small soluble oligomers, but forms fibrils
more slowly than wild-type a-synuclein in vitro [21]. If A30P
were genuinely a pathogenic mutation, then this would
support the notion that oligomers, not fibrils, are the toxic
species.
Interestingly, one case with the A30P mutation has been
shown recently to have rather extensive Lewy pathology
that, by extension, represents fibrillar a-synuclein [22], a sur-
prising finding given that previous work suggested A30P
forms fibrils less readily than wild-type a-synuclein. How-
ever, one thing to consider is that the material deposited in
this case might include wild-type protein. In many assays,A30P a-synuclein behaves as a loss-of-function protein: for
example, it lacks the ability to bind lipids, a feature that char-
acterizes all synucleins [23]. It is therefore possible that the
wild-type allele is upregulated to compensate for a loss-of-
function protein. The wild-type allele has also been reported
to be expressed at relatively higher levels than the A53T
variant [24,25]. I acknowledge that this idea is provocative,
and that data on the relative expression of E46K are not
available, but these findings might imply that mutations at
the SNCA locus all include an element of increased expres-
sion of the normal human protein.
At the cellular level, the toxicity of a-synuclein has been
ascribed to effects on any number of different subcellular
functions, including effects on protein-turnover systems
and energy generation via mitochondria [26]. One class of
genes that play a role in a-synuclein toxicity, initially identi-
fied from studies in yeast, are those involved in trafficking
of lipid vesicles through the cell [27], which is particularly
interesting as a-synuclein is normally a lipid-binding protein.
The mechanism involved may involve disruption of Rabs,
small GTPases that regulate crucial aspects of lipid mem-
brane trafficking [28]. Furthermore, several experiments
have shown that manipulating the level of expression of dif-
ferent Rab homologues can overcome the toxic effects of
synuclein in several different species [29,30]. Therefore, the
toxicity of a-synuclein may be intimately tied to its normal
cellular role of binding lipids; whether this is related to aggre-
gation is unclear.
Overall, these data show that there is at least one protein in
our brain that, at levels similar to those normally expressed,
can be toxic and that toxicity may relate to normal function.
Are there other proteins with the same properties?
LRRK2 and MAPT Are Additional PD-associated Genes
A second gene associated with PD is leucine-rich repeat
kinase 2 (LRRK2) [31,32], which, as the name implies, is
one of two homologous kinases in the human genome that
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Figure 2. The synuclein family.
The tree on the left of the figure shows that there are several synuclein homologues in many vertebrate species. These separate into three groups,
identified as a-, b- and g-synuclein and, interestingly, most species have one of each homologue. Exceptions to this general rule include species
such as the lamprey and zebrafish, which appear to have evolved multiple g-synuclein homologues but lack an a-synuclein homologue. On the
right are ideograms of the proteins. The characteristic KTEGV repeats, the number of which varies between homologues, are indicated in yellow.
Mutations in a-synuclein, shown in red, are associated with autosomal dominant PD and include three point mutations and multiplications of the
whole SNCA locus (indicated by the horizontal line). NAC, non-amyloid component.
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R755contain leucine-rich repeats (Figure 3). LRRK1 and LRRK2
are also part of the larger family of ROCO proteins with
tandem ROC (Ras of complex proteins) and COR (C-terminal
of ROC) bidomains [33]. The function of theROC–COR region
is to bind and hydrolyze GTP, possibly through dimerization
mediated by the COR domain [34]. The domain structure of
LRRK2 is probably relevant for PD because most of the
convincing PD-associated mutations are found within the
ROC–COR and kinase domains. In fact, it appears likely
that there is co-regulation of these two portions of the mole-
cule [35], so PD-associated mutations may have slightly
different biochemical effects, but all presumably impact the
overall function of the protein.
The relevant function(s) of LRRK2 in PD is not yet clear,
although clues may be gleaned from understanding where
the protein is expressed. LRRK2 appears to be associated
with several different vesicular compartments in cells, in-
cluding in neurons. Membrane association of LRRK2 has
been reported in several studies [36,37], and it has been sug-
gested that it is the kinase-active form of LRRK2 that is found
in these fractions [38]. Of the many membrane-bound struc-
tures in cells, there is strong evidence for LRRK2 association
with vesicles of the endosomal system that are involved
in autophagy [39] and with synaptic vesicles [40,41]. Like
a-synuclein, mutant LRRK2 is toxic when overexpresseddirectly in neurons [42–47]. Toxicity can be limited by muta-
tions that impact normal functions like kinase activity and
GTP binding [42–47], suggesting that, as with a-synuclein,
the normal function of LRRK2 in neurons may be relevant
for toxicity.
LRRK2 is also expressed in microglia [48–50], resident
immunologically active cells of the brain that have been
shown to contribute to neurodegeneration in other diseases,
including ALS and tauopathies. Whether this microglial ex-
pression of LRRK2 contributes to disease is not clear, but
it has been suggested that LRRK2 mutant microglia might
release cytokines that are neurotoxic [51]. Therefore, in the
case of LRRK2, cell-autonomous and non cell-autonomous
mechanisms may both be at play.
Perhapsmore importantly, deletion of LRRK2mitigates the
toxicity associated with A53T a-synuclein [52], suggesting
that LRRK2 and a-synuclein are in the same pathway.
A caveat to this result is that the pathology associated
with expression of A53T a-synuclein driven by alternative
promoters does not respond to LRRK2 deletion [53,54].
However, the pathology arising from most human LRRK2
mutations includes a-synuclein-positive Lewy bodies, al-
though some cases do not fit to this general pattern [55,56].
LRRK2 is therefore suggested to be genetically ‘upstream’
of a-synuclein with two provisos: either not all cases go
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Figure 3. The LRRK family.
Like the synucleins, there are at least two
distinct branches of the LRRK family repre-
sented by LRRK1 (lower part of the tree)
and LRRK2 (upper part of the tree) in verte-
brate species. The invertebrate LRRKs form
a group that sits between the two vertebrate
LRRK homologues (see text). The distinction
between the LRRK1 and LRRK2 orthologues
includes differences at the amino terminus,
where LRRK2 (upper ideogram) includes a
series of repeat sequences that LRRK1 (lower
ideogram) lacks. Other domains include the
anykrin-like repeats (ANK), leucine-rich re-
peats (LRR), and the Ras of complex proteins
(ROC) and C-terminal of ROC (COR), kinase
and WD40 domains.
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a-synuclein into Lewy bodies is not required for disease
pathogenesis.
As discussed above, support for a role of a-synuclein in
sporadic disease is provided by the existence of PD-associ-
ated variants around the SNCA locus. The same appears to
be true for variants around the LRRK2 locus [57]. If we follow
the logic outlined for the effects of the wild-type a-synuclein
protein, and further assume that the association is not the
result of rare amino acid variants of LRRK2, then this implies
that wild-type human LRRK2 can contribute to disease risk.
The mechanistic basis of the genetic association is unclear;
the effect could be due to increased LRRK2 expression but
other mechanisms, such as altered splicing and changes in
RNA localization, cannot yet be ruled out. But, when consid-
ered together with the observation that LRRK2mutants have
a disease that is clinically similar to sporadic PD and often
have a-synuclein-positive pathology, these genetic observa-
tions suggest thatmore than one normal protein, when accu-
mulated or misregulated, can lead to neurodegenerative
disease.
There are almost certainly other genes in the same cate-
gory. The power of genome-wide association studies, per-
formed by looking for statistical over-representation of
genetic variants in a comparison of many thousands of PD
cases and controls, is to identify in a relatively unbiased
way some of the underlying genetic architecture of sporadic
PD. Recent large-scale studies [58–60] suggest that there are
many variants that influence the lifetime risk of PD. Although
each variant alone has a small effect, cumulatively thesesmall effects explain a significant pro-
portion of the overall risk of PD to the
general population.
Going through each of the PD risk
loci is outside of the scope of this
article, but there is one additional risk
factor gene, MAPT, that is worth dis-
cussing. Variation at the MAPT locus
influences lifetime risk of PD to al-
most the same extent as a-synuclein
[58–60]. The MAPT gene encodes tau
[61] which, in contrast to a-synuclein,
is not a deposited protein in PD
(see below). This shows that proteins
can be involved in neurodegenera-
tion without being deposited and, byextrapolation, that a-synuclein might still be involved in the
LRRK2 cases of PD that show no signs of Lewy bodies.
Tau is a member of a family of microtubule-binding proteins
(MAPs), whose normal function is to bind to and stabilize
microtubules. This normal function is tightly regulated by
modification of the MAPs; for example, MAPT function is
controlled by alternative splicing and by a number of phos-
phorylation events.
It is possible that the role of tau in PD is related to LRRK2
and/or a-synuclein. There is evidence that LRRK2 may influ-
ence tau, including some biochemical effects via altered
phosphorylation [62–64] and the accumulation of phosphor-
ylated tau in LRRK2 mouse models [65,66]. This may be
related to the ability of LRRK2 to bind to tau-bound microtu-
bules, a property that several mutations in LRRK2 exag-
gerate [67]. However, tau expression is not required for
neurodegeneration in models involving expression of a-syn-
uclein [68]. Overall, the data hint that there might be rela-
tionships between these different proteins, but the precise
nature of the underlying pathways is obscure.
What is clear is that mutations in these different genes are
only part of the spectrum of changes that occur in PD and
that normal proteins may play an important role in the
same processes by acting as risk factors. Furthermore, the
pathological roles are potentially related to normal roles
and expression in the nervous system. We might therefore
ask whether this is specific to PD or whether some of the
same principles, perhaps even for the same proteins, apply
to other neurodegenerative conditions. Other reviews on
neurodegeneration are available that cover more examples
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more depth.
Alzheimer’s and Frontotemporal Dementias: Additional
Roles of Tau
The MAPT gene was introduced above as a risk factor gene
for PD; however, what wasn’t discussed is that the patholog-
ical involvement of tau is much more characteristic of AD. In
AD, but not PD, tau protein is heavily phosphorylated and
deposited as insoluble forms in neurofibrillary tangles [69].
Tangles and similar pathologies are found in a number of
diseases collectively termed tauopathies. Like a-synuclein,
tau is prone to aggregate. The feature that distinguishes
AD from other tauopathies is that, in AD, another protein
fragment, amyloid b (Ab), accumulates in extracellular de-
posits called amyloid plaques. A general concept of AD path-
ogenesis is that Ab generation drives tau pathology and it
is the latter that is most strongly associated with neuronal
damage and cell death [70,71]. Ab is generated via pre-
senilin-mediated cleavage from amyloid b precursor protein
(APP); presenilins and APP each contain mutations that
cause familial early onset AD [72]. All of the mutations seem
to increase the generation of Ab and, because Ab-containing
plaques define the pathology of sporadic AD, the Mendelian
forms of this disease have helped to connect the genetics
and neuropathology in what seems to be a straightforward
manner.
In contrast, point mutations inMAPT do not cause AD but
instead cause frontotemporal dementia (FTD), sometimes
with accompanying parkinsonism [73]. Although both AD
and FTD are dementias in a broad sense, to my mind they
involve distinct disease processes. FTD, as its name implies,
primarily affects the frontal portion of the cerebral cortex,
whereas AD affects other cortical and subcortical regions
(such as the entorhinal cortex and hippocampus) earlier in
the disease course. Additionally, FTD is not a plaque dis-
ease. It is also important to note there are other pathologies
that can be associated with FTD, particularly FTD associated
with ALS, but here I will focus on tau pathologies.
In contrast to PD, common variation around the MAPT
locus is not a risk factor for sporadic AD, although it does
contribute to risk of progressive supranuclear palsy (PSP)
[74], a disease involving tau deposition and PD-like symp-
toms. Therefore, the contribution of MAPT/tau to differ-
ent neurodegenerative conditions is surprisingly complex:
causal mutations are found in one condition (FTD), but com-
mon variation around this locus contributes to the lifetime
risk of others (PD and PSP), and the protein is deposited in
yet others (including AD). This then leads to the question of
the evolutionary origin of proteins like a-synuclein and tau
and why they would be present in our brain.
The Varied Evolutionary History of Genes Associated
with Neurodegeneration
What is known about the evolutionary history of neurode-
generation-associated proteins? To start with a-synuclein,
Homo sapiens has two additional homologues, b- and g-syn-
uclein, with distinct sequences but overall high homology
(Figure 2). Most vertebrate species, including teleost and
cartilaginous fish, lizards, birds and mammals, have at least
one homologue, although the number varies. Zebrafish, for
example, have no a-synuclein homologue but two g-synu-
cleins [75]. Lampreys have at least two g-synuclein genes
[76], but it is not known whether older vertebrate groupsdo. In contrast, the synucleins are apparently absent from
bacteria, plants and invertebrates, including the important
model organisms Drosophila melanogaster and Caenorhab-
ditis elegans. Therefore, the presence of the synucleins
seems tomark the separation of vertebrate from invertebrate
animals (Figure 2).
This evolutionary history is interesting because it implies
that none of the synucleins are actually required to make
a functioning neuron: flies and worms have nervous systems
that do quite fine without these genes. Supporting this,
mouse synuclein knockouts are viable and have working
brains, although there is controversy as to whether neuro-
degeneration occurs in a-/b-/g-synuclein triple knockouts
[77–79]. Subtle phenotypes, including changes in vocaliza-
tion, have also been reported in a-synuclein knockout mice
[80]. But overall, the brains of vertebrates seem to spend
a lot of energy generating three proteins that are not essen-
tial to make or maintain a nervous system.
It is also interesting that Ala53, one of the amino acids
mutated in AD, is not a particularly well-conserved residue.
In fact, the same residue is a threonine in rodent homologues
of a-synuclein and therefore A53T is a revertant mutation.
The alteration from threonine to alanine specifically distin-
guishes New World from Old World primates [81], a separa-
tion that is estimated to have occurred w35 million years
ago. Conservation is often used as a supportive argument
for pathogenicity in human genetics studies as it is used to
suggest that the residue must be ‘important’, but here this
is clearly not the case. Mice (or most other species) are not
known to suffer from PD in the wild, so simply possessing
a threonine residue at position 53 is not sufficient to cause
Lewy body disease. But, A53T is pathogenic in the context
of the human protein and human brain.
LRRK1 and LRRK2 are also part of a larger protein family,
the ROCO proteins, representatives of which are found in
many species, including evolutionarily ‘old’ species, such
as cyanobacteria and slime molds [33]. Because the ROCO
domain is found in a large number of structurally diverse
multidomain proteins, it is likely that this region is more
ancient than other portions of LRRK2, including the kinase
domain by which it is named, which were acquired later.
Interestingly, in some anemone species there are four
LRRK paralogues, and it has been suggested that different
homologues were lost in the vertebrate and invertebrate
lineages. Therefore, the LRRK proteins in important model
organisms such as Drosophila and C. elegans are not strict
orthologues of LRRK2 but slightly different proteins (Fig-
ure 3). Functional conservation between the different LRRK
proteins is not well understood, although LRRK1 and LRRK2
certainly have different biochemical properties [82].
The various mutations in LRRK2 are relatively well con-
served in different species and homologues. For example,
the most common mutation is G2019S, found in the kinase
domain, specifically in the Mg2+-binding motif at the amino-
terminal portion of the activation loop, and within the DYG
or DFG sequence found in all known protein kinases.
G2019S is an activating mutation in LRRK2 [35]. Activating
mutations in this motif have also been reported in other
kinases in many cancers, and in some cases the invariant
glycine residue was replaced by a serine, as in LRRK2 [83].
Mutations in the ROC–COR domains are also found at resi-
dues that are reasonably well conserved between homo-
logues and species, and the mutant forms tend to have
lower GTP hydrolysis activity compared with the wild-type
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Figure 4. MAPT.
MAPT, encoding the axonal microtubule-
binding protein tau, is found in most verte-
brates, and conservation generally follows
the standard phylogenetic tree for these
organisms (as shown on the left of this
figure). There are many other microtubule-
binding proteins but, for clarity, here I have
shown the nearest group, which includes the
dendritic microtubule-binding protein MAP2.
These are a separate group of proteins but
again these follow the same phylogenetic
pattern across species. The protein structure
of the six known tau isoforms is shown on
the right. These isoforms are generated
by alternative splicing of exons 2 and 3 (in
green in the ideograms) generating different
numbers of amino-terminal inserts (2 N,1 N
or 0 N) and by splicing of exon 10, which
generates one extra microtubule-binding re-
peat (4R or 3R). A selection of the known
exonic FTD mutations is shown in red. In
orange are intronic mutations that change
the splicing but not the amino-acid sequence,
numbered by nucleotide position relative to
exon 10.
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residues that are likely to be important in the control of catal-
ysis and are conserved, presumably due to evolutionary
constraints on which amino acids are tolerated.
Because tau is one of many microtubule-binding proteins
it should also be considered part of a gene family (Figure 4).
However, sequence analysis suggests that MAPT genes in
different species are closely related to only one additional
brain protein (MAP2) and to MAP4, which is expressed out-
side of the central nervous system [83]. Even within this
group there is likely to be functional specification, with tau
being found in axons and MAP2 proteins in dendrites. There
are some evolutionarily old microtubule-binding proteins,
but close homologues of MAPT are found only in animals,
where they show reasonable levels of conservation.
All genes in the MAP2/tau family show extensive splicing
and, interestingly, there are differences between splicing in
different species. For example, inmice exon 10 of tau, which,
when included in the mRNA results in the production of a
form of tau protein that has four rather than three microtu-
bule-binding repeats (4R tau in contrast to 3R tau), has low
levels of inclusion in MAPT mRNA in mouse embryos but
rises during development to near complete inclusion in
adults, i.e., the tau in adult mice is predominantly 4R tau
[84]. In contrast, the normal human adult brain contains
both 4R and 3R tau at apparently equimolar amounts [85].
The mutations in tau associated with FTD include both
point mutations and mutations in splice sites [86]. Therefore,
both the sequence of the tau protein and the relative inclu-
sion of specific exons is important in determining the risk
of dementias. The role of splicing in tau is further emphasized
by the fact that there is variation in the deposited tau spe-
cies in different tauopathies. For example, in AD there is
deposition of both 3R and 4R tau, whereas in PSP 4R taupredominates [87]. This demonstrates
that, for a protein such as tau, the
underlying protein structure may be
important in understanding how itmay play roles in different diseases. I suspect that tau has
the general capacity to be neurotoxic but that there are
multiple ways in which it can be detrimental to neurons,
by changing the balance of splicing, by overall net expres-
sion levels or by accumulation of modifications such as
phosphorylation.
One interesting aspect of the evolutionary history ofMAPT
is that the locus on chromosome 17 in which theMAPT gene
is situated appears to have undergone inversion at several
times in different species [88]. In humans, the two inverted
versions of the locus are named H1 and H2; H1 is the more
frequent version but is evolutionarily the more recent form
[89]. Some authorities have speculated that the retention of
H2 seen in some human populations may have come from
interbreeding with Homo neanderthalensis [90], although
full support for this idea would require sequencing the
MAPT region in samples from Neanderthals. H2 is protective
against the lifetime risk of PD and PSP, but is absent from
Asian populations, which explains why signals were seen
in genome-wide association studies performed in samples
of European [74,91] but not Japanese [92] ancestry.
The overall message from the history of these genes is
that they appear to have relatively little in common with
each other, apart from being expressed in the brain. How-
ever, in two cases humans and primates have sequence
differences (for SCNA) or splicing differences (MAPT) that
distinguish them from other organisms. Many of these other
organisms are used as model systems, each with their own
advantages and disadvantages, but of course none are hu-
man. Where model systems lack a close homologue, e.g.,
for a-synuclein in yeast, flies and worms, it is important to
validate results in species that do [30]. Even within verte-
brate species, it is interesting that removal of endogenous
murine homologues of SNCA [93] or MAPT [94] produces
Special Issue
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teins. Therefore, in at least some circumstances our most
convenient models may need to be ‘humanized’ to provide
better models.
Is Neurodegeneration Subject to Evolutionary
Constraints?
Why would we have in our brains proteins such as a-synu-
clein or tau that, without substantive modification, appear
to be able to accumulate and cause some rather distressing
diseases? One argument is that evolutionary forces will be
generally neutral because neurodegeneration occurs in a
period of life that, for most people throughoutmost of human
history, is post-reproductive. I would concur that the pres-
ence of neurodegenerative diseases at reasonable popula-
tion frequencies in people over 50 years old does imply
that there is not strong evolutionary selection against those
diseases.
But this does not mean that there is not selection at the
same loci for beneficial properties of the same protein. Over-
all we see that, although neurodegeneration is not likely to
have been selected for and may not have been selected
against, we have proteins that are apparently dispensable
for CNS function but that are expressed at levels close to
those needed to trigger neurodegeneration.
For example, the fact that expression of a-synuclein is
relatively high, and close to the threshold needed to cause
disease, suggests that, even if not necessary for CNS func-
tion, this protein likely plays an important role in the human
brain. In this context it is interesting that the known roles of
a-synuclein relate to plasticity [95] and/or stress [96]. There-
fore, in a long-lived species like humans, where chronic
stress may have a cumulative effect, the role of a-synuclein
might be especially important in keeping the brain func-
tioning to its highest level. Therefore, the levels of a-synu-
clein protein may have been selected for, and there may be
a delicate balancing act in keeping within an appropriate
concentration range.
Loci for other neurodegenerative diseases are also sub-
jected to evolutionary forces. For example, the MAPT inver-
sion has been shown to be under purifying selection in some
populations [89]. The reasons for this selection are not clear,
although there appears to be an association between the
more recent allele andwomen havingmore children. Another
observation is that several infectious diseases that affect
the brain cause tauopathy [96] and it is therefore possible
that certain brain diseasesmay contribute some of the selec-
tion, although again this is difficult to test. Perhaps most
dramatically tau is required for the normal development of
the human brain — deletions at the locus are associated
with severe developmental problems in children [97]. It is
likely, therefore, that the structural role that tau plays in
strengthening axons is beneficial for the development of
the human brain.
Part of what makes human tau different from tau in other
species is the more complex mix of isoforms discussed
above. The relevance of this is uncertain, although interest-
ingly the presence of 3R can inhibit the aggregation of 4R
tau in mixtures of the two in vitro [98]. The human brain is
relatively large compared with other species, and I wonder
whether there is adaptation for higher levels of tau protein
to support longer axons of neurons in the brain that, in
turn, might require the presence of 3R tau to prevent 4R
protein constantly aggregating.There is also evidence of purifying selection at the LRRK2
locus, acting to remove rare deleterious alleles [99]. Again,
whether this has anything to dowith PD, or even normal brain
function, is unknown. The LRRK2 locus is a risk factor for
Crohn’s disease and leprosy. The molecular basis of this
association is unclear [100], but may be related to the ex-
pression of LRRK2 in immune cells, as discussed above.
The main point is that many, perhaps all, of the genes that
are associated with neurodegeneration have been selected
for because of properties that are beneficial in the context
of the human brain or other tissues. Following from this,
those proteins are evolutionarily advantageous, even if
redundancy of other proteins in the same family masks the
effects of loss-of-function mutations in model organisms.
The generally post-reproductive phenotypes of late-onset
neurodegeneration are not strong enough for purifying
selection to remove the specific alleles associated with
neurodegenerative disease even if those phenotypes are
unpleasant. Therefore, pathogenic alleles persist in the pop-
ulation and this may, in part, be due to these alleles having
subtle effects where disease processes are initiated in the
context of a specific organ in a long-lived species where
chronic stress and other stochastic processes abound.
Conclusions
The human brain expresses a number of genes that when
mutated or expressed at higher levels contribute to the risk
of neurodegenerative diseases. It seems likely that the
expression of these genes and their regulation has been
selected for over our evolutionary history, even as the
specific alleles that endow an increased risk of disease are
not strongly selected against. It is not clear that these
considerations help cure diseases and in some cases simple
arguments about conservation of residues isn’t helpful, even
in understanding pathogenicity, but understanding the
evolutionary history of genes like SNCA, MAPT and LRRK2
helps place their function into context and should influence
our views about model organisms. Some of these consider-
ations suggest why alleles persist in the human population
and why, especially as the population ages, neurodegen-
erative diseases are going to remain a significant medical
problem.
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